The Portal Hypertension drugs in development market research report provides comprehensive information on the therapeutics under development for Portal Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Portal Hypertension. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Portal Hypertension and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Portal Hypertension by six companies/universities/institutes. The top development phase for Portal Hypertension is phase ii with five drugs in that stage. The Portal Hypertension pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Portal Hypertension pipeline products market are: AstraZeneca, Galectin Therapeutics and Shaanxi Micot Technology.
The key targets in the Portal Hypertension pipeline products market include Thromboxane A2 Receptor (Prostanoid TP Receptor or TBXA2R), Sodium/Glucose Cotransporter 2 (Low Affinity Sodium-Glucose Cotransporter or Solute Carrier Family 5 Member 2 or SGLT2 or SLC5A2), and Soluble Guanylate Cyclase (sGC or EC 4.6.1.2).
The key mechanisms of action in the Portal Hypertension pipeline product include Bile Acid Receptor (Farnesoid X Activated Receptor or Farnesol Receptor HRR 1 or Nuclear Receptor Subfamily 1 Group H Member 4 or Retinoid X Receptor Interacting Protein 14 or FXR or NR1H4) Agonist with one drug in Unknown. The Portal Hypertension pipeline products include four routes of administration with the top ROA being Oral and three key molecule types in the Portal Hypertension pipeline products market including Small Molecule, and Synthetic Peptide.
Portal Hypertension overview
Portal hypertension is increased pressure within the portal venous system. It is determined by the increased portal pressure gradient (the difference in pressures between the portal venous pressure and the pressure within the inferior vena cava or the hepatic vein. This pressure gradient is normally less than or equal to 5 mmHg. A pressure gradient of 6 mmHg or more between the portal and hepatic veins (or inferior vena cava) suggests the presence of portal hypertension
For a complete picture of Portal Hypertension’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
